FDA Recalls Clonidine Transdermal Patches for Delivery System Defect
Mayne Pharma is recalling 1,440 cartons of Clonidine transdermal patches nationwide due to an out-of-specification defect in the release liner that could affect proper drug delivery.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses, injuries, or hospitalizations. The defect was identified through routine stability testing and represents a precautionary recall for a manufacturing specification failure in the transdermal delivery system.
Plain-English summary
Mayne Pharma Inc is recalling 1,440 cartons of Clonidine (Clonidine) 0.3 mg/day transdermal patches nationwide. The patches are subject to recall due to a defect in the transdermal delivery system identified during stability testing: the release liner removal force fails to meet manufacturing specifications at the 3-month stability timepoint.
Clonidine is a prescription medication used to treat high blood pressure and ADHD. When the release liner does not perform to specification, there is a potential risk that the patch may not deliver the medication correctly or consistently to patients.
The affected product is Clonidine Transdermal System, USP 0.3 mg/day, 4 Patches per Carton (NDC 51862-455-01 and 51862-455-04), Lot 41179A with an expiration date of January 2023.
Patients currently using patches from the affected lot should contact their pharmacist or healthcare provider. Do not stop taking Clonidine without medical guidance, as abrupt discontinuation can cause serious blood pressure changes. Patients should speak with their healthcare provider about replacement medication or alternative batches.
The recalled product
- Product
- CLONIDINE (CLONIDINE)
- Brand
- CLONIDINE
- Manufacturer
- Mayne Pharma Inc
- Category
- Drug — Transdermal Patch
- Affected units
- 1,440
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot: 41179A Exp. Jan 2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · CLONIDINE
- ModerateX-Gen Recalls Clonidine Injection Vials Due to Labeling Error
FDA (Drugs) · 2019-04-17
- LowX-Gen Recalls Clonidine HCl Injection Due to Labeling Error
FDA (Drugs) · 2014-07-30
Same manufacturer · Mayne Pharma Inc
See all →- ModerateLexette Topical Foam Recall Due to Dispensing Defects
FDA (Drugs) · 2022-01-26
- ModerateMayne Pharma Recalls Carbidopa and Levodopa Tablets Due to Foreign Tablet Mix-Up
FDA (Drugs) · 2020-03-18
- LowMayne Pharma Recalls Oxycodone and Acetaminophen Tablets Due to Labeling Error
FDA (Drugs) · 2018-09-05
- ModerateMayne Pharma Recalls Fabior Foam Due to Stability Test Failures
FDA (Drugs) · 2018-04-11
- ModerateMayne Pharma Recalls Liothyronine Sodium Tablets for Dissolution Failures
FDA (Drugs) · 2017-12-06
Same hazard · delivery system defect
See all →- ModerateSimethicone Oral Syringe Recalled for Defective Delivery System
FDA (Drugs) · 2025-03-12
- HighMorphine Sulfate Oral Syringes Recalled for Defective Delivery System Leakage
FDA (Drugs) · 2025-03-12
- ModerateVitamin D Supplement Oral Syringes Recalled for Defective Delivery System
FDA (Drugs) · 2025-03-12
- SevereFentanyl Transdermal Patches Recalled for Defective Delivery System
FDA (Drugs) · 2025-02-26
- HighPrescription Dextroamphetamine Patches Recalled for Defective Adhesive System
FDA (Drugs) · 2024-11-27